University Medical Center Göttingen
Welcome,         Profile    Billing    Logout  
 39 Trials 
35 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hasenkamp, Justin
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
NCT03853616 / 2017-002848-32: MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)

Recruiting
1/2
48
Europe
MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells
Miltenyi Biomedicine GmbH
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory
12/24
12/24
Wiltfang, Jens
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT06149013: Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

Completed
N/A
50
Europe
MindAhead Active, MindAhead's Behavioral Activation Therapy, Treatment-as-usual, TAU
MindAhead UG, University Medical Center Göttingen
Mild Cognitive Impairment, Mild Dementia
10/24
10/24
Arnim, Christine von
NCT06149013: Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

Completed
N/A
50
Europe
MindAhead Active, MindAhead's Behavioral Activation Therapy, Treatment-as-usual, TAU
MindAhead UG, University Medical Center Göttingen
Mild Cognitive Impairment, Mild Dementia
10/24
10/24
Quintel, Michael
ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated
3
440
Europe
Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%
Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany
Septic Shock
07/22
06/23
NCT04249414: Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography

Suspended
N/A
22
Europe
PulmoVista 500
Drägerwerk AG & Co. KGaA, University of Göttingen, Prof. Dr. med. Imhoff
Mechanical Ventilation, Ventilation Perfusion Mismatch
06/24
12/24
Moster, Mark L
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Kunsch, Steffen
HADRIAN, NCT05517369: Impact of Hybrid-ESD+ and LiftUp® on the en Bloc/R0 Rate in Colorectal Adenomas Between 2 and 3 cm

Withdrawn
N/A
60
Europe
Hybrid ESD+
Wuerzburg University Hospital, Waid City Hospital, Zurich, University Hospital Ulm, Rems-Murr-Klinikum Winnenden, Insel Gruppe AG, University Hospital Bern, Klinikum Ludwigsburg, Mathilden Hospital Herford, St. Franziskus Hospital Münster, Agaplesion Kliniken Kassel, Ovesco Endoscopy AG
Colorectal Adenoma
04/24
10/24
Korsten, Peter
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Active, not recruiting
2/3
301
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen, Horizon Therapeutics USA, Inc
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
09/25
09/25
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
RHEACT, NCT05204784: Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis

Recruiting
N/A
30
Europe
Rheopheresis treatment, Intravenous Infusion
Peter Korsten, DiaMed GmbH
Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma
12/23
06/24
Seidler, Tim
BENCHMARK, NCT04579445: Setting a Benchmark for Resource Utilization and Quality of Care in Patients Undergoing TAVI in Europe

Completed
N/A
2408
Europe, RoW
Education on tailored Quality Improvement measures, Education on Quality of Care Improvement measures
Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences
Transcatheter Aortic Valve Implantation (TAVI)
04/23
08/24
NCT02387112: Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation

Active, not recruiting
N/A
102
Europe
Early VAD implantation
German Heart Institute, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Helmholtz Zentrum München, University Medicine Greifswald, University of Göttingen
End Stage Heart Disease
03/24
12/24
Tang, Rosa
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Recruiting
3
143
Europe, US
Intervention/Treatment
Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/25
03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT04607369: Implementation of the NEDS EyeCTester App

Enrolling by invitation
N/A
100
US
EyeCTester
Neuro-Eye Diagnostic Systems, LLC, Neuro-ophthalmology of Texas PLLC
Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
01/23
01/23
Mörer, Onnen
ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated
3
440
Europe
Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%
Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany
Septic Shock
07/22
06/23
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting
2
95
Europe
Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution
Apeptico Forschung und Entwicklung GmbH
ARDS
12/24
12/24
NCT04249414: Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography

Suspended
N/A
22
Europe
PulmoVista 500
Drägerwerk AG & Co. KGaA, University of Göttingen, Prof. Dr. med. Imhoff
Mechanical Ventilation, Ventilation Perfusion Mismatch
06/24
12/24
Zerr, Inga
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Shafie, Rami El
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
PACCELIO, NCT06102057 / 2022-003408-33: - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting
2
110
Europe
standard Radiotherapy, standard, Chemotherapy, Immunotherapy, Experimental Radiotherapy, Experimental
TheraOp, AstraZeneca
Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
06/26
06/28
Lane, Kathleen
NCT03639025: OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Active, not recruiting
N/A
458
US
OCS Lung System
TransMedics
Lung Transplantation
11/25
11/29
MOMENTIS, NCT05526560: Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

Recruiting
N/A
500
Europe, Canada, US
MITRIS RESILIA Mitral Valve, Model 11400M
Edwards Lifesciences
Mitral Stenosis, Mitral Valve Insufficiency
01/28
12/35
Sala, Elisa
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)

Recruiting
2
387
Europe
Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo
MaaT Pharma
Transplant Complication
10/26
02/27
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Recruiting
1
90
Europe
Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP)
AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH
Acute Myeloid Leukemia (AML)
05/25
09/25
NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Recruiting
1
37
Europe
Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment
AvenCell Europe GmbH, Allucent (NL) BV
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
12/25
06/26
TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting
N/A
150
Europe, RoW
No Intervention
Takeda
Cytomegalovirus (CMV)
04/25
04/25
Hill, Eddie
PANTHER, NCT04545502: Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Recruiting
N/A
2000
Europe, Canada, US
Gelsoft Plus Vascular Graft, Gelsoft Plus, Vascular Bypass Graft, Gelsoft Plus Extra Anatomical, Cardiovascular Patch, Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics, Gelweave Vascular Graft, Gelweave, Gelweave Valsalva Vascular Graft, Gelweave Valsalva
Vascutek Ltd.
Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
01/26
01/33
Stefko, Susan
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Kreuser, Anna L
No trials found
Marschner, Felix
No trials found

Download Options